Match!
Bo Ahrén
Lund University
EndocrinologyGlucagonInsulinDiabetes mellitusMedicine
857Publications
88H-index
32.7kCitations
What is this?
Publications 853
Newest
#1Bo Ahrén (Lund University)H-Index: 88
#2Yuchiro Yamada (Akita University)H-Index: 2
Last. Yutaka SeinoH-Index: 58
view all 3 authors...
Abstract Glucose-dependent insulinotropic polypeptide (GIP) receptor knockout (KO) mice are tools for studying GIP physiology. Previous results have demonstrated that these mice have impaired insulin response to oral glucose. In this study, we examined the insulin response to intravenous glucose by measuring glucose, insulin and C-peptide after intravenous glucose (0.35 g/kg) in 5-h fasted female GIP receptor KO mice and their wild-type (WT) littermates. The 1 min insulin and C-peptide responses...
1 CitationsSource
#1Bo Ahrén (Lund University)H-Index: 88
#2Yuichiro Yamada (Akita University)H-Index: 34
Last. Yutaka SeinoH-Index: 58
view all 3 authors...
To establish the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) for the incretin effect after oral glucose, studies were undertaken in female mice with genetic deletion of receptors for GIP and GLP-1 (double incretin receptor knockout [DIRKO] mice) and their wild-type (WT) counterparts. Insulin secretion was explored after oral glucose (doses ranging from 0 to 100 mg), after intravenous glucose (doses ranging from 0 to 0.75 g/kg), and after...
Source
#1Wathik Alsalim (Lund University)H-Index: 4
#2Olga Göransson (Lund University)H-Index: 22
Last. Bo Ahrén (Lund University)H-Index: 88
view all 6 authors...
Aim: Dipeptidyl peptidase-4 (DPP-4) inhibition has effects on both fasting and postprandial glucose. However, the extent of this effect over the whole day and whether different DPP-4 inhibitors have the same effects have not been established. We therefore explored the whole day effects of three different DPP-4 inhibitors versus placebo on glucose, islet and incretin hormones after ingestion of breakfast, lunch and dinner in subjects with metformin-treated and well-controlled type 2 diabetes. Met...
Source
#1Johan Farngren (Lund University)H-Index: 4
#2Bo Ahrén (Lund University)H-Index: 88
Abstract Hypoglycaemia is common in both type 1 and type 2 diabetes and has both acute and long-term consequences. Therefore, a key to proper glucose-lowering therapy in diabetes is to avoid or prevent hypoglycaemia. Incretin therapy (DPP-4 inhibitors and GLP-1 receptor agonists) offers an advantage in this respect, because it reduces glucose with a low risk of hypoglycaemia, both in monotherapy and in combination with other therapies. The reason for this low risk of hypoglycaemia is the glucose...
Source
#1Sheyda Sofizadeh (University of Gothenburg)H-Index: 1
#2Henrik Imberg (Chalmers University of Technology)H-Index: 3
Last. Marcus Lind (University of Gothenburg)H-Index: 16
view all 11 authors...
Introduction The effects of the GLP-1 analogue liraglutide on time in hypoglycaemia, time in hyperglycaemia, and time in range for type 2 diabetes patients initially treated with multiple daily insulin injections (MDI) were investigated. Variables associated with hypoglycaemia in the current population were also identified.
1 CitationsSource
#1Daniela Jakubowicz (Wolfson Medical Center)H-Index: 28
#2Zohar Landau (Wolfson Medical Center)H-Index: 13
Last. Oren Froy (HUJI: Hebrew University of Jerusalem)H-Index: 36
view all 13 authors...
OBJECTIVE In type 2 diabetes, insulin resistance and progressive β-cell failure require treatment with high insulin doses, leading to weight gain. Our aim was to study whether a three-meal diet (3Mdiet) with a carbohydrate-rich breakfast may upregulate clock gene expression and, as a result, allow dose reduction of insulin, leading to weight loss and better glycemic control compared with an isocaloric six-meal diet (6Mdiet). RESEARCH DESIGN AND METHODS Twenty-eight volunteers with diabetes (BMI ...
3 CitationsSource
In the 1990s it was discovered that the enzyme dipeptidyl peptidase-4 (DPP-4) inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). DPP-4 inhibition results in raised levels of the two incretin hormones which in turn result in lowering of circulating glucose through stimulation of insulin secretion and inhibition of glucagon secretion. Since then, several small orally available molecules have been developed with DPP-4 inhibitory...
Source
#1Wathik Alsalim (Lund University)H-Index: 4
#2Bo Ahrén (Lund University)H-Index: 88
Source
#1S. S. Ahmadi (University of Gothenburg)H-Index: 1
#2Karin Filipsson (Lund University)H-Index: 14
Last. Marcus Lind (University of Gothenburg)H-Index: 16
view all 12 authors...
1 CitationsSource
Today, glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering drugs used in the management of type 2 diabetes. Their development emerged from the understanding that a combined islet dysfunction comprising of impaired insulin secretion and exaggerated glucagon secretion is the key defect of hyperglycemia. GLP-1 was shown to target these defects, and after the discovery that dipeptidyl peptidase-4 inactivates native GLP-1, several different dipeptidyl peptidase-4-resist...
7 CitationsSource
12345678910